Depomed Targets Impax, Par Over Generic Epilepsy Drug

Law360, New York (April 11, 2012, 6:44 PM EDT) -- Drug company Depomed Inc. on Tuesday sued Impax Laboratories Inc. and Par Pharmaceutical Cos. Inc. in New Jersey federal court, accusing the companies of making a generic version of Depomed's Gralise epilepsy medication before the patents on the drug expired.

Depomed said that both Impax and Par notified it at the end of March that they planned to file abbreviated new drug applications with the U.S. Food and Drug Administration to make generic Gralise.

But Depomed argues the ANDAs are premature, as the last of the...
To view the full article, register now.